Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
Brain-based Mechanisms of Emotion Regulation in Aging and Mood Disorders
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 12, 2021
Transoral Incisionless Fundoplication (TIF) Registry
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 17, 2021
COVID-19 Compatible Accelerated TMS Therapy
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 31, 2021
A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects with Type 2 Diabetes on Insulin Therapy
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 2, 2021
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 5, 2021
A Randomized Phase 3 Trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 26, 2021
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination with Ruxolitinib in Participants with Anemia Due to Myeloproliferative Disorders
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 24, 2021
A Phase 2 Trial of Paxalisib Combined with a Ketogenic Diet and Metformin for Newly Diagnosed and Recurrent Glioblastoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 11, 2022
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 18, 2022
A Phase II Study to Test the Efficacy of AB928 (Dual Adenosine Receptor Antagonist) and AB122 (a PD1 Checkpoint Inhibitor) in Combination With Short Course Radiotherapy and Consolidation Chemotherapy for Rectal Cancer (PANTHER)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 18, 2022